284 related articles for article (PubMed ID: 24274756)
1. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
Hemnes AR; Brittain EL; Trammell AW; Fessel JP; Austin ED; Penner N; Maynard KB; Gleaves L; Talati M; Absi T; Disalvo T; West J
Am J Respir Crit Care Med; 2014 Feb; 189(3):325-34. PubMed ID: 24274756
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
Talati MH; Brittain EL; Fessel JP; Penner N; Atkinson J; Funke M; Grueter C; Jerome WG; Freeman M; Newman JH; West J; Hemnes AR
Am J Respir Crit Care Med; 2016 Sep; 194(6):719-28. PubMed ID: 27077479
[TBL] [Abstract][Full Text] [Related]
3. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
Johnson JA; Hemnes AR; Perrien DS; Schuster M; Robinson LJ; Gladson S; Loibner H; Bai S; Blackwell TR; Tada Y; Harral JW; Talati M; Lane KB; Fagan KA; West J
Am J Physiol Lung Cell Mol Physiol; 2012 Mar; 302(5):L474-84. PubMed ID: 22180660
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Yasuda T; Tada Y; Tanabe N; Tatsumi K; West J
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L667-74. PubMed ID: 21856816
[TBL] [Abstract][Full Text] [Related]
5. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
Talati M; West J; Blackwell TR; Loyd JE; Meyrick B
Am J Physiol Lung Cell Mol Physiol; 2010 Sep; 299(3):L363-73. PubMed ID: 20562228
[TBL] [Abstract][Full Text] [Related]
6. Fat and cardiotoxicity in hereditary pulmonary hypertension.
Tuder RM; Robinson JC; Graham BB
Am J Respir Crit Care Med; 2014 Feb; 189(3):247-9. PubMed ID: 24484329
[No Abstract] [Full Text] [Related]
7. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle.
van der Bruggen CE; Happé CM; Dorfmüller P; Trip P; Spruijt OA; Rol N; Hoevenaars FP; Houweling AC; Girerd B; Marcus JT; Mercier O; Humbert M; Handoko ML; van der Velden J; Vonk Noordegraaf A; Bogaard HJ; Goumans MJ; de Man FS
Circulation; 2016 May; 133(18):1747-60. PubMed ID: 26984938
[TBL] [Abstract][Full Text] [Related]
8. A potential role for insulin resistance in experimental pulmonary hypertension.
West J; Niswender KD; Johnson JA; Pugh ME; Gleaves L; Fessel JP; Hemnes AR
Eur Respir J; 2013 Apr; 41(4):861-71. PubMed ID: 22936709
[TBL] [Abstract][Full Text] [Related]
9. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
[TBL] [Abstract][Full Text] [Related]
10. Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Frump AL; Lowery JW; Hamid R; Austin ED; de Caestecker M
PLoS One; 2013; 8(11):e80319. PubMed ID: 24224048
[TBL] [Abstract][Full Text] [Related]
11. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
West J; Harral J; Lane K; Deng Y; Ickes B; Crona D; Albu S; Stewart D; Fagan K
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L744-55. PubMed ID: 18723761
[TBL] [Abstract][Full Text] [Related]
12. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
Feng F; Harper RL; Reynolds PN
Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Kabwe JC; Sawada H; Mitani Y; Oshita H; Tsuboya N; Zhang E; Maruyama J; Miyasaka Y; Ko H; Oya K; Ito H; Yodoya N; Otsuki S; Ohashi H; Okamoto R; Dohi K; Nishimura Y; Mashimo T; Hirayama M; Maruyama K
Respir Res; 2022 Apr; 23(1):87. PubMed ID: 35395852
[TBL] [Abstract][Full Text] [Related]
14. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.
Prewitt AR; Ghose S; Frump AL; Datta A; Austin ED; Kenworthy AK; de Caestecker MP
J Biol Chem; 2015 Jan; 290(2):960-71. PubMed ID: 25411245
[TBL] [Abstract][Full Text] [Related]
15. Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension.
Brittain EL; Talati M; Fessel JP; Zhu H; Penner N; Calcutt MW; West JD; Funke M; Lewis GD; Gerszten RE; Hamid R; Pugh ME; Austin ED; Newman JH; Hemnes AR
Circulation; 2016 May; 133(20):1936-44. PubMed ID: 27006481
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.
Chen X; Talati M; Fessel JP; Hemnes AR; Gladson S; French J; Shay S; Trammell A; Phillips JA; Hamid R; Cogan JD; Dawson EP; Womble KE; Hedges LK; Martinez EG; Wheeler LA; Loyd JE; Majka SJ; West J; Austin ED
Circulation; 2016 Jan; 133(1):82-97. PubMed ID: 26487756
[TBL] [Abstract][Full Text] [Related]
17. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension.
Gomez-Arroyo J; Mizuno S; Szczepanek K; Van Tassell B; Natarajan R; dos Remedios CG; Drake JI; Farkas L; Kraskauskas D; Wijesinghe DS; Chalfant CE; Bigbee J; Abbate A; Lesnefsky EJ; Bogaard HJ; Voelkel NF
Circ Heart Fail; 2013 Jan; 6(1):136-44. PubMed ID: 23152488
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension in a large family with mean clinical follow-up of 12 years.
Hinderhofer K; Fischer C; Pfarr N; Szamalek-Hoegel J; Lichtblau M; Nagel C; Egenlauf B; Ehlken N; Grünig E
PLoS One; 2014; 9(3):e91374. PubMed ID: 24621962
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers.
Chida A; Shintani M; Yagi H; Fujiwara M; Kojima Y; Sato H; Imamura S; Yokozawa M; Onodera N; Horigome H; Kobayashi T; Hatai Y; Nakayama T; Fukushima H; Nishiyama M; Doi S; Ono Y; Yasukouchi S; Ichida F; Fujimoto K; Ohtsuki S; Teshima H; Kawano T; Nomura Y; Gu H; Ishiwata T; Furutani Y; Inai K; Saji T; Matsuoka R; Nonoyama S; Nakanishi T
Am J Cardiol; 2012 Aug; 110(4):586-93. PubMed ID: 22632830
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Pfarr N; Szamalek-Hoegel J; Fischer C; Hinderhofer K; Nagel C; Ehlken N; Tiede H; Olschewski H; Reichenberger F; Ghofrani AH; Seeger W; Grünig E
Respir Res; 2011 Jul; 12(1):99. PubMed ID: 21801371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
